Overview
PNC-27 is a synthetic 32-amino acid peptide studied for selective targeting of cancer cells. It contains an HDM-2-binding domain linked to a membrane-penetrating sequence.
Critical Warning: No human clinical trials exist. The FDA explicitly warns that PNC-27 products are unapproved with no established safety data.
Quick Reference
– Reconstitution: 3.0 mL bacteriostatic water yields 10 mg/mL concentration
– Typical Daily Dose: 100–500 mcg once daily via subcutaneous injection
– Easy Measurement: 1 unit on U-100 insulin syringe = 100 mcg
– Storage (Lyophilized): -20°C or colder
– Storage (Reconstituted): 2–8°C; avoid freeze-thaw cycles
Dosing Protocol: Gradual Titration Approach
| Week Range | Daily Dose | Syringe Units |
|---|---|---|
| 1-2 | 100 mcg | 1 unit (0.01 mL) |
| 3-4 | 200 mcg | 2 units (0.02 mL) |
| 5-8 | 300 mcg | 3 units (0.03 mL) |
| 9-12 | 400 mcg | 4 units (0.04 mL) |
| 13-16 | 500 mcg | 5 units (0.05 mL) |
Frequency: Once daily subcutaneous injection
Cycle Duration: 8–16 weeks recommended
Administration: Consistent daily timing with site rotation
Reconstitution Instructions
1. Draw 3.0 mL bacteriostatic water with sterile syringe
2. Inject slowly along vial wall; avoid foaming
3. Gently swirl or roll until dissolved (do not shake)
4. Label clearly with reconstitution date
5. Refrigerate at 2–8°C protected from light
Supplies Needed (per cycle duration)
For 8-week protocol:
– 1 vial PNC-27 (30 mg)
– 56 U-100 insulin syringes (7/week)
– 1 bottle bacteriostatic water (10 mL)
– 2 boxes alcohol swabs (100-count each)
For 12-week protocol:
– 1 vial PNC-27
– 84 syringes
– 1 bottle bacteriostatic water
– 2 boxes alcohol swabs
For 16-week protocol:
– 2 vials PNC-27
– 112 syringes
– 1 bottle bacteriostatic water
– 3 boxes alcohol swabs
How It Works
The peptide combines a p53 tumor suppressor segment with a membrane-penetrating leader sequence. Preclinical research indicates selective binding to HDM-2 on cancer cell surfaces, inducing membrane destabilization and necrotic cell death while theoretically sparing normal cells. Animal studies showed growth inhibition via intraperitoneal administration.
Injection Technique
– Clean vial stopper and injection site with alcohol; allow drying
– Pinch skinfold; insert needle at 45–90° angle into subcutaneous tissue
– Do not aspirate for subcutaneous injections
– Inject slowly and steadily
– Rotate sites systematically (abdomen, thighs, upper arms)
– Avoid repeated site use to prevent lipohypertrophy
Important Precautions
– Use new sterile syringes only; dispose in sharps container
– Rotate injection sites to minimize local irritation
– Document daily doses and site rotation for consistency
– Possible injection-site reactions include redness and irritation
– “No authoritative human dosing exists for PNC-27” per preclinical literature
Lifestyle Support
– Maintain balanced, nutrient-dense diet
– Prioritize adequate sleep and stress management
– Consult qualified healthcare professionals before use
Safety & Efficacy Notes
Preclinical Observations:
– Selective cytotoxicity toward cancer cells with abnormal p53/HDM-2 expression
– Mechanism involves direct membrane lysis rather than apoptosis
– No human safety data available
– Any dosing exceeding a few hundred micrograms daily remains speculative
Regulatory Status
“The FDA explicitly warns that PNC-27 products are unapproved and lack established safety data.” This protocol is strictly educational and not medical advice.
—
Disclaimer: This content is for research and educational purposes only. It is not medical advice. Consult healthcare professionals before any experimental peptide use.